Form4insider filings, from the source

SEC Form 4 · accession 0001140361-18-002443

Loxo Oncology, Inc. · LOXO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Joshua H. Bilenker
Officer — President & CEO · Director
Period of report
Jan 16, 2018
Accepted (ET)
Jan 18, 2018 · 5:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockJan 16, 2018M7,500$1.184A190,207D
Common StockF2,F3Jan 16, 2018S2,919$86.4236D187,288D
Common StockF2,F4Jan 16, 2018S1,604$87.1245D185,684D
Common StockF2,F5Jan 16, 2018S600$88.7767D185,084D
Common StockF2,F6Jan 16, 2018S1,577$89.9387D183,507D
Common StockF2,F7Jan 16, 2018S800$90.4964D182,707D
Common StockJan 17, 2018M7,500$1.184A190,207D
Common StockF2,F8Jan 17, 2018S1,104$86.1929D189,103D
Common StockF2,F9Jan 17, 2018S1,042$87.1416D188,061D
Common StockF2,F10Jan 17, 2018S2,672$88.8921D185,389D
Common StockF2,F11Jan 17, 2018S2,682$89.5249D182,707D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Employee Stock Option (right to buy)F12$1.184Jan 16, 2018M7,500D—Nov 14, 2023Common Stock7,50082,190D
Employee Stock Option (right to buy)F12$1.184Jan 17, 2018M7,500D—Nov 14, 2023Common Stock7,50074,690D

Explanation of responses